CN102850339B - New neurokinin (NK-1) receptor antagonist crystal form and preparation method thereof - Google Patents
New neurokinin (NK-1) receptor antagonist crystal form and preparation method thereof Download PDFInfo
- Publication number
- CN102850339B CN102850339B CN201210394457.6A CN201210394457A CN102850339B CN 102850339 B CN102850339 B CN 102850339B CN 201210394457 A CN201210394457 A CN 201210394457A CN 102850339 B CN102850339 B CN 102850339B
- Authority
- CN
- China
- Prior art keywords
- aprepitant
- crystal formation
- preparation
- water
- thf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000002464 receptor antagonist Substances 0.000 title abstract description 5
- 229940044551 receptor antagonist Drugs 0.000 title abstract description 5
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 claims abstract description 54
- 229960001372 aprepitant Drugs 0.000 claims abstract description 54
- 239000000843 powder Substances 0.000 claims abstract description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 60
- 230000015572 biosynthetic process Effects 0.000 claims description 30
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000001186 cumulative effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- -1 (trifluoromethyl) phenyl Chemical group 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000000634 powder X-ray diffraction Methods 0.000 description 6
- 235000015320 potassium carbonate Nutrition 0.000 description 5
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 3
- ZLRBJVJEQXBAAI-UHFFFAOYSA-N 5-(chloromethyl)-1,2-dihydro-1,2,4-triazol-3-one Chemical compound ClCC1=NC(=O)NN1 ZLRBJVJEQXBAAI-UHFFFAOYSA-N 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- MDTUWBLTRPRXBX-UHFFFAOYSA-N 1,2,4-triazol-3-one Chemical compound O=C1N=CN=N1 MDTUWBLTRPRXBX-UHFFFAOYSA-N 0.000 description 1
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical compound Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940108890 emend Drugs 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 102220014894 rs76757102 Human genes 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210394457.6A CN102850339B (en) | 2012-10-17 | 2012-10-17 | New neurokinin (NK-1) receptor antagonist crystal form and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210394457.6A CN102850339B (en) | 2012-10-17 | 2012-10-17 | New neurokinin (NK-1) receptor antagonist crystal form and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102850339A CN102850339A (en) | 2013-01-02 |
CN102850339B true CN102850339B (en) | 2014-10-15 |
Family
ID=47397368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210394457.6A Active CN102850339B (en) | 2012-10-17 | 2012-10-17 | New neurokinin (NK-1) receptor antagonist crystal form and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102850339B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103788082A (en) * | 2012-10-30 | 2014-05-14 | 天津卡普希科技有限公司 | Preparation method of aprepitant III crystal form substance |
CN111943904B (en) * | 2019-05-15 | 2023-05-05 | 南京正大天晴制药有限公司 | Refining method of key intermediate of neurokinin 1 receptor antagonist |
CN110776502B (en) * | 2019-12-06 | 2021-04-20 | 广州白云山汉方现代药业有限公司 | Refining method of aprepitant |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1106390C (en) * | 1997-07-02 | 2003-04-23 | 麦克公司 | Polymorphic form of tachykinin receptor antagonist 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-5(oxo-1H,4H-1,2,4-triazolo methylmorpholine |
WO2007044829A2 (en) * | 2005-10-06 | 2007-04-19 | Dr. Reddy's Laboratories Ltd. | Preparation of aprepitant |
WO2007088483A1 (en) * | 2006-02-03 | 2007-08-09 | Glenmark Pahrmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
WO2007112457A2 (en) * | 2006-03-29 | 2007-10-04 | Dr. Reddy's Labortories, Ltd. | Aprepitant polymorph mixtures |
WO2008044102A1 (en) * | 2006-10-13 | 2008-04-17 | Glenmark Pharmaceuticals Limited | Polymorph form of aprepitant and process for the preparation thereof |
WO2008104512A2 (en) * | 2007-02-27 | 2008-09-04 | Sandoz Ag | Novel polymorphs of aprepitant and processes for preparation |
WO2010140132A1 (en) * | 2009-06-02 | 2010-12-09 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline aprepitant having form i content |
CN102525879A (en) * | 2010-12-31 | 2012-07-04 | 江苏正大天晴药业股份有限公司 | Method for preparing aprepitant solid dispersing composition |
-
2012
- 2012-10-17 CN CN201210394457.6A patent/CN102850339B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1106390C (en) * | 1997-07-02 | 2003-04-23 | 麦克公司 | Polymorphic form of tachykinin receptor antagonist 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-5(oxo-1H,4H-1,2,4-triazolo methylmorpholine |
WO2007044829A2 (en) * | 2005-10-06 | 2007-04-19 | Dr. Reddy's Laboratories Ltd. | Preparation of aprepitant |
WO2007088483A1 (en) * | 2006-02-03 | 2007-08-09 | Glenmark Pahrmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
WO2007112457A2 (en) * | 2006-03-29 | 2007-10-04 | Dr. Reddy's Labortories, Ltd. | Aprepitant polymorph mixtures |
WO2008044102A1 (en) * | 2006-10-13 | 2008-04-17 | Glenmark Pharmaceuticals Limited | Polymorph form of aprepitant and process for the preparation thereof |
WO2008104512A2 (en) * | 2007-02-27 | 2008-09-04 | Sandoz Ag | Novel polymorphs of aprepitant and processes for preparation |
WO2010140132A1 (en) * | 2009-06-02 | 2010-12-09 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline aprepitant having form i content |
CN102525879A (en) * | 2010-12-31 | 2012-07-04 | 江苏正大天晴药业股份有限公司 | Method for preparing aprepitant solid dispersing composition |
Non-Patent Citations (3)
Title |
---|
Doris E. Braun,等.Packing polymorphism of a conformationally flexible molecule (aprepitant).《New Journal of Chemistry》.2008,第32卷(第10期),第1677-1685页. * |
Karel M. J. Brands,等.Efficient Synthesis of NK1 Receptor Antagonist Aprepitant Using a Crystallization-Induced Diastereoselective Transformation.《J. Am. Chem. Soc.》.2003,第125卷(第8期),第2129-2135页. * |
Roy Helmy,等.Characterization and Quantitation of Aprepitant Drug Substance Polymorphs by Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy.《Anal. Chem.》.2002,第75卷(第3期),第605-611页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102850339A (en) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106083714B (en) | N- (4- { [bis- (methyl oxygroup) quinolyl-4s of 6,7-] oxygroup } phenyl)-N '-(4- fluorophenyl) cyclopropane -1,1- diformamide malate and its crystal type | |
CN103282365B (en) | (8S, 9R) 5 fluorine 8 (4 fluorophenyl) 9 (base of 1 methyl 1H, 1,2,4 triazoles 5) 8,9 dihydro 2H pyridos [4,3,2 de] phthalazines 3 (7H) ketone toluene fulfonate of crystallization | |
CN102850339B (en) | New neurokinin (NK-1) receptor antagonist crystal form and preparation method thereof | |
CN101362718B (en) | 4-(4-benzamido phenoxy)-2-(methylcarbamoyl) pyridine derivatives, preparation method and application thereof | |
CN102757397A (en) | Process for synthesizing CETP inhibitor | |
EP2825538B1 (en) | Positive allosteric modulators of mglur2 | |
CN102066376B (en) | Anhydrous crystal form of orvepitant maleate | |
CN107810183A (en) | (S) crystalline fumarate salt of [3,4 difluoro 2 (idodophenylamino of 2 fluorine 4) phenyl] [base of 3 hydroxyl 3 (base of piperidines 2) azetidine 1] ketone | |
CN102491931A (en) | 3-substituted indolone derivative and preparation method and application thereof | |
CN104693127B (en) | Gefitinib ethylene glycol solvent compound and its production and use | |
CN107043345A (en) | Preparation, structure and the purposes of the diketone Schiff base of 4-acetylbiphenyl hydrazone indoline 2,3 | |
CN110054613A (en) | Substituted amino-quinazoline compound and its medical composition and its use | |
CN103788112A (en) | Method for preparing biotin by debenzylating benzyl biotin | |
CN104159584A (en) | Aprepitant L-proline solvates - compositions and cocrystals | |
CN106565755B (en) | Using 1- pyridine -6- methoxy-p-carbolines as copper nitrate (II) chelate and its synthetic method of ligand and application | |
CN104628663A (en) | Synthesis method of 3-chloromethyl-1,2,4-triazoline-5-one | |
CN102924303B (en) | Tapentadol hydrochloride crystal form C, and preparation method and application thereof | |
CN114008023B (en) | Crystal form of Sofos-piramide and preparation method thereof | |
CN114057656A (en) | Favipiravir eutectic crystal and preparation method thereof | |
CN102391290A (en) | Cefoxitin anhydrous crystal, preparation method thereof and method for preparing cefoxitin sodium by using same | |
Bredikhin et al. | Synthesis, phase behavior and absolute configuration of β-adrenoblocker bupranolol and related compounds | |
CN102268003B (en) | Unsymmetrical poly-substituted porphyrin gold (III) type anticancer compound and preparation method thereof | |
CN103254088B (en) | Tapentadol hydrochloride crystal form D as well as preparation method and application thereof | |
CN112830919B (en) | Benzopiperidine derivatives as pharmaceutical agents and process for preparing them | |
Bredikhina et al. | One more chiral drug prone to spontaneous resolution: Binary phase diagram, absolute configuration, and crystal packing of bevantolol hydrochloride |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN SELECTION PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI BOCIMED PHARMACEUTICAL CO., LTD. Effective date: 20150302 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 570100 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150302 Address after: 570100 Haikou, Meilan District, Hainan Province Shunda Road, No. 6 Patentee after: HAINAN SELECTION PHARMACEUTICAL CO.,LTD. Address before: 201203 Shanghai city Pudong New Area Zhangjiang Cailun Road No. 781 room 1006 Patentee before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170424 Address after: 201203 Shanghai Jing Pudong New Area Free Trade Zone Road No. 351 Building No. 2 room A679-04 Patentee after: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. Address before: 570100 Haikou, Meilan District, Hainan Province Shunda Road, No. 6 Patentee before: HAINAN SELECTION PHARMACEUTICAL CO.,LTD. |
|
CP03 | Change of name, title or address |
Address after: 201203 Building 1, Lane 647, Songtao Road, Zhangjiang High Tech Park, Pudong New Area, Shanghai Patentee after: Shanghai Yunshengyan neoplasm Technology Co.,Ltd. Address before: Room a679-04, building 2, no.351, GuoShouJing Road, Pudong New Area pilot Free Trade Zone, Shanghai 201203 Patentee before: SHANGHAI BOCIMED PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address |